{"id":"generic-latanoprost","safety":{"commonSideEffects":[{"rate":"25-50","effect":"Conjunctival hyperemia"},{"rate":"10-20","effect":"Iris pigmentation increase"},{"rate":"10-15","effect":"Eyelash growth (hypertrichosis)"},{"rate":"5-15","effect":"Eye irritation/discomfort"},{"rate":"5-10","effect":"Periocular skin pigmentation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Latanoprost acts as a selective agonist of the prostaglandin F (FP) receptor, primarily located on the ciliary muscle bundle and trabecular meshwork of the eye. By activating these receptors, it enhances drainage of aqueous humor through the unconventional uveoscleral pathway, reducing intraocular pressure. This mechanism makes it effective for treating glaucoma and ocular hypertension.","oneSentence":"Latanoprost is a prostaglandin F analog that binds to prostaglandin F receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:40:30.309Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT05165290","phase":"PHASE3","title":"Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure","status":"UNKNOWN","sponsor":"TearClear Corp","startDate":"2021-11-29","conditions":"Elevated Intraocular Pressure","enrollment":300},{"nctId":"NCT02047630","phase":"PHASE4","title":"Efficacy of the Brand-name Latanoprost and One of Its Generic Version in Primary Open Angle Glaucoma and Ocular Hypertension","status":"TERMINATED","sponsor":"CHU de Quebec-Universite Laval","startDate":"2014-01","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":60},{"nctId":"NCT01162603","phase":"PHASE4","title":"Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP)","status":"COMPLETED","sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","startDate":"2011-03","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Generic latanoprost","genericName":"Generic latanoprost","companyName":"CHU de Quebec-Universite Laval","companyId":"chu-de-quebec-universite-laval","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Generic latanoprost is a small molecule that acts as a prostanoid FP receptor agonist, targeting the Prostaglandin F2-alpha receptor. It is used to treat conditions such as Primary Open Angle Glaucoma, Ocular Hypertension, and Elevated Intraocular Pressure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}